US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IN8bio, Inc.

2.24

+0.05002.28%

Volume:30.14K

Turnover:66.95K

Market Cap:10.17M

PE:-0.17

High:2.25

Open:2.19

Low:2.19

Close:2.19

52wk High:16.86

52wk Low:1.98

Shares:4.54M

Float Shares:4.03M

Volume Ratio:0.55

T/O Rate:0.75%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-13.0307

EPS(LYR):-17.0525

ROE:-165.56%

ROA:-69.05%

PB:0.67

PE(LYR):-0.13

Loading ...

Overview Company News Filings

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research

HC Wainwright Adjusts IN8bio Price Target to $6 From $8, Maintains Buy Rating

MT Newswires Live

IN8bio Is Maintained at Buy by HC Wainwright & Co.

IN8bio Reports Progress in Cancer Therapies

IN8BIO Q4 Net Income USD -6.4 Million

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio announces gamma-delta T cell enager platform

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

INAB: Continued Survival in INB-100 Trial

Zacks Small Cap Research

IN8bio presented Phase 1 data on INB-100 at 2025 TCT

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Mizuho Securities Keeps Their Buy Rating on IN8bio (INAB)

BUZZ-IN8bio rises on early-stage data from cancer therapy

Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), IN8bio (INAB)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/INAB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INAB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INAB\",,,,,undefined,":{"symbol":"INAB","market":"US","secType":"STK","nameCN":"IN8bio, Inc.","latestPrice":2.24,"timestamp":1756238400000,"preClose":2.19,"halted":0,"volume":30136,"delay":0,"floatShares":4029300,"shares":4539717,"eps":-13.03071,"marketStatus":"Pre-Mkt","change":0.05,"latestTime":"08-27 05:17:12 EDT","open":2.19,"high":2.25,"low":2.19,"amount":66954.11555199999,"amplitude":0.027397,"askPrice":2.54,"askSize":152,"bidPrice":2.2,"bidSize":258,"shortable":3,"etf":0,"ttmEps":-13.03071,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1756301400000},"marketStatusCode":1,"adr":0,"listingDate":1605157200000,"exchange":"NASDAQ","adjPreClose":2.24,"postHourTrading":{"tag":"盘后","latestPrice":2.27,"preClose":2.24,"latestTime":"19:58 EDT","volume":360,"amount":816.18,"timestamp":1756252688910},"volumeRatio":0.5525770875687191},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INAB\",,,,,undefined,":{"symbol":"INAB","floatShares":4029300,"roa":"-69.05%","roe":"-165.56%","lyrEps":-17.05248,"volumeRatio":0.5525770875687191,"shares":4539717,"dividePrice":0,"high":2.25,"amplitude":0.027397,"preClose":2.19,"low":2.19,"week52Low":1.98,"pbRate":"0.67","week52High":16.86,"institutionHeld":0,"latestPrice":2.24,"committee":0.258537,"eps":-13.03071,"divideRate":0,"volume":30136,"delay":0,"ttmEps":-13.03071,"open":2.19,"prevYearClose":7.716,"prevWeekClose":2.26,"prevMonthClose":2.13,"prevQuarterClose":2.09,"fiveDayClose":2.28,"twentyDayClose":2.2,"sixtyDayClose":4.446},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INAB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"INAB","fiscalQuarterEnding":"2025/06","expectedEps":-1.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-1.24},{"market":"US","date":"2025-06-06","symbol":"INAB","defaultRemindTime":1749216600000,"type":"split","dateTimestamp":1749182400000,"forFactor":30,"toFactor":1,"ratio":30},{"market":"US","date":"2025-05-07","symbol":"INAB","fiscalQuarterEnding":"2025/03","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2021-09-10","symbol":"INAB","fiscalQuarterEnding":"2021/06","expectedEps":-0.3,"name":null,"time":"","type":"earning","dateTimestamp":1631246400000,"reportTimeType":"","actualEps":1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INAB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INAB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1739332800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/INAB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"INAB","date":"2025-08-25","current":-0.429458,"percent":0.927122,"low":-60.555129,"twenty":-6.889324,"median":-1.748288,"eighty":-0.688198,"high":-0.259966,"avg":-7.55218,"sd":15.814422,"marketCap":10259760},"quantilePoints":[{"date":"2020-11-13","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-11-20","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-11-27","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-12-04","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-12-11","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-12-18","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-12-24","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2020-12-31","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-01-08","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-01-15","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-01-22","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-01-29","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-02-05","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-02-12","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-02-19","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-02-26","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-03-05","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-03-11","current":-60.555129,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":310890032},{"date":"2021-07-30","current":-20.321327,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":187545530},{"date":"2021-08-06","current":-19.792973,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":182669346},{"date":"2021-08-13","current":-19.000441,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":175355070},{"date":"2021-08-20","current":-15.667743,"twenty":-60.555129,"median":-60.555129,"eighty":-60.555129,"marketCap":144597603},{"date":"2021-08-27","current":-14.936176,"twenty":-60.555129,"median":-60.555129,"eighty":-22.35346,"marketCap":137845964},{"date":"2021-09-03","current":-16.907344,"twenty":-60.555129,"median":-60.555129,"eighty":-20.215656,"marketCap":156037880},{"date":"2021-09-10","current":-17.727589,"twenty":-60.555129,"median":-60.555129,"eighty":-20.040893,"marketCap":166727976},{"date":"2021-09-17","current":-13.958732,"twenty":-60.555129,"median":-60.555129,"eighty":-19.085791,"marketCap":131281871},{"date":"2021-09-24","current":-15.155194,"twenty":-60.555129,"median":-60.555129,"eighty":-18.138817,"marketCap":142534602},{"date":"2021-10-01","current":-14.736432,"twenty":-60.555129,"median":-60.555129,"eighty":-17.663778,"marketCap":138596146},{"date":"2021-10-08","current":-12.881915,"twenty":-60.555129,"median":-60.555129,"eighty":-16.140999,"marketCap":121154412},{"date":"2021-10-15","current":-11.984369,"twenty":-60.555129,"median":-60.555129,"eighty":-15.651486,"marketCap":112712988},{"date":"2021-10-22","current":-13.280736,"twenty":-60.555129,"median":-60.555129,"eighty":-14.97998,"marketCap":124905322},{"date":"2021-10-29","current":-15.135253,"twenty":-60.555129,"median":-60.555129,"eighty":-14.672621,"marketCap":142347057},{"date":"2021-11-05","current":-14.955784,"twenty":-60.555129,"median":-60.555129,"eighty":-14.748397,"marketCap":140659147},{"date":"2021-11-12","current":-14.224101,"twenty":-60.555129,"median":-60.555129,"eighty":-14.60881,"marketCap":158100881},{"date":"2021-11-19","current":-11.473771,"twenty":-60.555129,"median":-22.35346,"eighty":-14.426892,"marketCap":127530960},{"date":"2021-11-26","current":-11.389405,"twenty":-60.555129,"median":-22.35346,"eighty":-13.958732,"marketCap":126593232},{"date":"2021-12-03","current":-9.448987,"twenty":-60.555129,"median":-20.321327,"eighty":-13.818503,"marketCap":105025496},{"date":"2021-12-10","current":-11.170053,"twenty":-60.555129,"median":-20.199399,"eighty":-13.58292,"marketCap":124155140},{"date":"2021-12-17","current":-10.36014,"twenty":-60.555129,"median":-20.04699,"eighty":-13.380441,"marketCap":115152955},{"date":"2021-12-23","current":-10.377013,"twenty":-60.555129,"median":-19.843776,"eighty":-13.252819,"marketCap":115340500},{"date":"2021-12-31","current":-7.407331,"twenty":-60.555129,"median":-19.000441,"eighty":-12.570834,"marketCap":82332487},{"date":"2022-01-07","current":-7.230163,"twenty":-60.555129,"median":-18.461926,"eighty":-12.206067,"marketCap":80363259},{"date":"2022-01-14","current":-6.833643,"twenty":-60.555129,"median":-17.887117,"eighty":-11.984528,"marketCap":75955939},{"date":"2022-01-21","current":-5.419838,"twenty":-60.555129,"median":-17.727589,"eighty":-11.677476,"marketCap":60241499},{"date":"2022-01-28","current":-5.061958,"twenty":-60.555129,"median":-16.898705,"eighty":-11.301664,"marketCap":56263659},{"date":"2022-02-04","current":-5.483787,"twenty":-60.555129,"median":-16.175776,"eighty":-10.967575,"marketCap":60952297},{"date":"2022-02-11","current":-7.069867,"twenty":-60.555129,"median":-15.983021,"eighty":-10.387137,"marketCap":78581577},{"date":"2022-02-18","current":-6.81677,"twenty":-60.555129,"median":-15.647422,"eighty":-10.120541,"marketCap":75768394},{"date":"2022-02-25","current":-7.322965,"twenty":-60.555129,"median":-15.411038,"eighty":-9.418616,"marketCap":81394760},{"date":"2022-03-04","current":-7.13736,"twenty":-60.555129,"median":-15.198094,"eighty":-9.287005,"marketCap":79331759},{"date":"2022-03-11","current":-5.399421,"twenty":-60.555129,"median":-15.055489,"eighty":-7.731297,"marketCap":60014569},{"date":"2022-03-18","current":-3.748845,"twenty":-60.555129,"median":-14.955784,"eighty":-7.444452,"marketCap":54931819},{"date":"2022-03-25","current":-4.288062,"twenty":-60.555129,"median":-14.796256,"eighty":-7.302717,"marketCap":62832971},{"date":"2022-04-01","current":-4.416447,"twenty":-60.555129,"median":-14.626756,"eighty":-7.171106,"marketCap":64714198},{"date":"2022-04-08","current":-5.289466,"twenty":-60.555129,"median":-14.428142,"eighty":-7.076617,"marketCap":77506540},{"date":"2022-04-14","current":-4.4687,"twenty":-60.555129,"median":-14.426579,"eighty":-6.951755,"marketCap":65479857},{"date":"2022-04-22","current":-4.64754,"twenty":-60.555129,"median":-14.038496,"eighty":-6.889324,"marketCap":68100406},{"date":"2022-04-29","current":-3.081242,"twenty":-60.555129,"median":-13.958732,"eighty":-6.820145,"marketCap":45149440},{"date":"2022-05-06","current":-3.346101,"twenty":-60.555129,"median":-13.77786,"eighty":-6.48268,"marketCap":49030411},{"date":"2022-05-13","current":-2.840843,"twenty":-60.555129,"median":-13.659616,"eighty":-6.014858,"marketCap":52370949},{"date":"2022-05-20","current":-2.237931,"twenty":-60.555129,"median":-13.521562,"eighty":-5.632272,"marketCap":41256251},{"date":"2022-05-27","current":-2.411651,"twenty":-60.555129,"median":-13.380441,"eighty":-5.517534,"marketCap":44458791},{"date":"2022-06-03","current":-2.707998,"twenty":-60.555129,"median":-13.280736,"eighty":-5.419838,"marketCap":49921948},{"date":"2022-06-10","current":-2.452527,"twenty":-60.555129,"median":-13.051414,"eighty":-5.315055,"marketCap":45212330},{"date":"2022-06-17","current":-2.3299,"twenty":-60.555129,"median":-12.582799,"eighty":-5.161081,"marketCap":42951713},{"date":"2022-06-24","current":-2.483183,"twenty":-60.555129,"median":-12.363448,"eighty":-4.711057,"marketCap":45777484},{"date":"2022-07-01","current":-2.268587,"twenty":-60.555129,"median":-12.190881,"eighty":-4.552535,"marketCap":41821405},{"date":"2022-07-08","current":-2.499738,"twenty":-60.555129,"median":-12.131058,"eighty":-4.42415,"marketCap":46082667},{"date":"2022-07-15","current":-2.217493,"twenty":-60.555129,"median":-11.984369,"eighty":-4.339416,"marketCap":40879482},{"date":"2022-07-22","current":-2.457636,"twenty":-60.555129,"median":-11.64557,"eighty":-4.254681,"marketCap":45306522},{"date":"2022-07-29","current":-2.595591,"twenty":-60.555129,"median":-11.473771,"eighty":-4.172515,"marketCap":47849716},{"date":"2022-08-05","current":-2.452527,"twenty":-60.555129,"median":-11.170053,"eighty":-3.923449,"marketCap":45212330},{"date":"2022-08-12","current":-1.544548,"twenty":-60.555129,"median":-11.035068,"eighty":-3.402872,"marketCap":34851171},{"date":"2022-08-19","current":-1.998049,"twenty":-60.555129,"median":-10.75666,"eighty":-3.158273,"marketCap":45083968},{"date":"2022-08-26","current":-2.128356,"twenty":-60.555129,"median":-10.377013,"eighty":-2.846974,"marketCap":48024227},{"date":"2022-09-02","current":-2.617009,"twenty":-60.555129,"median":-10.284211,"eighty":-2.79112,"marketCap":59050198},{"date":"2022-09-09","current":-2.682163,"twenty":-60.555129,"median":-9.879254,"eighty":-2.656101,"marketCap":60520327},{"date":"2022-09-16","current":-2.725599,"twenty":-60.555129,"median":-9.398368,"eighty":-2.67239,"marketCap":61500414},{"date":"2022-09-23","current":-2.160933,"twenty":-60.555129,"median":-9.330876,"eighty":-2.636466,"marketCap":48759292},{"date":"2022-09-30","current":-2.19351,"twenty":-60.555129,"median":-7.947273,"eighty":-2.595591,"marketCap":49494357},{"date":"2022-10-07","current":-2.258664,"twenty":-60.555129,"median":-7.736358,"eighty":-2.505541,"marketCap":50964486},{"date":"2022-10-14","current":-2.182651,"twenty":-60.555129,"median":-7.474824,"eighty":-2.483183,"marketCap":49249335},{"date":"2022-10-21","current":-1.607126,"twenty":-60.555129,"median":-7.415767,"eighty":-2.467985,"marketCap":36263192},{"date":"2022-10-28","current":-2.008908,"twenty":-60.555129,"median":-7.322965,"eighty":-2.452568,"marketCap":45328990},{"date":"2022-11-04","current":-1.954613,"twenty":-60.555129,"median":-7.225945,"eighty":-2.452527,"marketCap":44103882},{"date":"2022-11-11","current":-1.576798,"twenty":-45.274461,"median":-7.13736,"eighty":-2.40552,"marketCap":41898688},{"date":"2022-11-18","current":-1.318609,"twenty":-22.35346,"median":-7.086741,"eighty":-2.353137,"marketCap":35038084},{"date":"2022-11-25","current":-1.493809,"twenty":-22.35346,"median":-7.044557,"eighty":-2.336787,"marketCap":39693494},{"date":"2022-12-02","current":-1.954861,"twenty":-22.35346,"median":-6.951755,"eighty":-2.319682,"marketCap":51944572},{"date":"2022-12-09","current":-2.176166,"twenty":-21.947033,"median":-6.91379,"eighty":-2.291069,"marketCap":57825090},{"date":"2022-12-16","current":-1.576798,"twenty":-20.321327,"median":-6.867389,"eighty":-2.277598,"marketCap":41898688},{"date":"2022-12-23","current":-1.632125,"twenty":-20.30507,"median":-6.825207,"eighty":-2.25851,"marketCap":43368817},{"date":"2022-12-30","current":-2.130061,"twenty":-20.240042,"median":-6.79146,"eighty":-2.249935,"marketCap":56599982},{"date":"2023-01-06","current":-2.609555,"twenty":-20.207528,"median":-6.500397,"eighty":-2.249578,"marketCap":69341104},{"date":"2023-01-13","current":-2.130061,"twenty":-20.101857,"median":-6.293701,"eighty":-2.248149,"marketCap":56599982},{"date":"2023-01-20","current":-2.139282,"twenty":-20.065278,"median":-6.008422,"eighty":-2.222649,"marketCap":56845004},{"date":"2023-01-27","current":-2.102398,"twenty":-20.044957,"median":-5.763894,"eighty":-2.196076,"marketCap":55864917},{"date":"2023-02-03","current":-2.231493,"twenty":-19.951479,"median":-5.568153,"eighty":-2.194169,"marketCap":59295219},{"date":"2023-02-10","current":-1.779661,"twenty":-19.833615,"median":-5.517534,"eighty":-2.176617,"marketCap":47289163},{"date":"2023-02-17","current":-1.800593,"twenty":-19.573503,"median":-5.483787,"eighty":-2.16454,"marketCap":47845361},{"date":"2023-02-24","current":-1.346272,"twenty":-19.25649,"median":-5.405012,"eighty":-2.156798,"marketCap":35773149},{"date":"2023-03-03","current":-1.456925,"twenty":-18.976055,"median":-5.348802,"eighty":-2.139282,"marketCap":38713408},{"date":"2023-03-10","current":-1.171073,"twenty":-18.760649,"median":-5.247563,"eighty":-2.137131,"marketCap":31117739},{"date":"2023-03-17","current":-1.078862,"twenty":-18.468022,"median":-5.111519,"eighty":-2.129038,"marketCap":28667523},{"date":"2023-03-24","current":-1.134188,"twenty":-18.28513,"median":-4.724571,"eighty":-2.11729,"marketCap":30137653},{"date":"2023-03-31","current":-1.116819,"twenty":-17.994243,"median":-4.628283,"eighty":-2.093853,"marketCap":31852804},{"date":"2023-04-06","current":-1.013728,"twenty":-17.857797,"median":-4.525575,"eighty":-2.054716,"marketCap":28912545},{"date":"2023-04-14","current":-1.108228,"twenty":-17.737933,"median":-4.429286,"eighty":-2.044514,"marketCap":31607782},{"date":"2023-04-21","current":-0.9793,"twenty":-17.711636,"median":-4.39077,"eighty":-2.024631,"marketCap":27930624},{"date":"2023-04-28","current":-1.600107,"twenty":-17.499729,"median":-4.3009,"eighty":-2.010187,"marketCap":45636646},{"date":"2023-05-05","current":-2.002319,"twenty":-16.903888,"median":-4.281643,"eighty":-2.008908,"marketCap":57108152},{"date":"2023-05-12","current":-1.906138,"twenty":-16.800043,"median":-4.223869,"eighty":-2.008908,"marketCap":54364966},{"date":"2023-05-19","current":-3.134129,"twenty":-16.387118,"median":-4.172515,"eighty":-2.008908,"marketCap":93713596},{"date":"2023-05-26","current":-2.576951,"twenty":-16.167082,"median":-4.031292,"eighty":-2.009164,"marketCap":77053401},{"date":"2023-06-02","current":-3.044583,"twenty":-16.132305,"median":-3.87723,"eighty":-2.010187,"marketCap":91036064},{"date":"2023-06-09","current":-2.397858,"twenty":-16.013206,"median":-3.466397,"eighty":-2.010187,"marketCap":71698338},{"date":"2023-06-16","current":-2.109319,"twenty":-15.952836,"median":-3.338012,"eighty":-2.010187,"marketCap":63070737},{"date":"2023-06-23","current":-1.910326,"twenty":-15.724762,"median":-3.218941,"eighty":-2.008908,"marketCap":57120668},{"date":"2023-06-30","current":-1.611838,"twenty":-15.65555,"median":-3.138239,"eighty":-2.001778,"marketCap":48195563},{"date":"2023-07-07","current":-1.661586,"twenty":-15.570177,"median":-3.134129,"eighty":-1.998049,"marketCap":49683081},{"date":"2023-07-14","current":-1.691435,"twenty":-15.437001,"median":-3.034633,"eighty":-1.966279,"marketCap":50575591},{"date":"2023-07-21","current":-1.591939,"twenty":-15.343021,"median":-2.997073,"eighty":-1.948098,"marketCap":47600556},{"date":"2023-07-28","current":-1.238727,"twenty":-15.240995,"median":-2.910292,"eighty":-1.927198,"marketCap":37039183},{"date":"2023-08-04","current":-1.263601,"twenty":-15.206675,"median":-2.86549,"eighty":-1.903019,"marketCap":37782941},{"date":"2023-08-11","current":-1.144206,"twenty":-15.147218,"median":-2.826657,"eighty":-1.879294,"marketCap":34212900},{"date":"2023-08-18","current":-1.183602,"twenty":-15.103347,"median":-2.765993,"eighty":-1.844935,"marketCap":36025305},{"date":"2023-08-25","current":-1.059013,"twenty":-15.015607,"median":-2.720922,"eighty":-1.788034,"marketCap":32233167},{"date":"2023-09-01","current":-1.09016,"twenty":-14.955784,"median":-2.706296,"eighty":-1.751998,"marketCap":33181202},{"date":"2023-09-08","current":-1.005128,"twenty":-14.955784,"median":-2.665875,"eighty":-1.734645,"marketCap":30593068},{"date":"2023-09-15","current":-0.975953,"twenty":-14.951862,"median":-2.637688,"eighty":-1.702114,"marketCap":29705076},{"date":"2023-09-22","current":-1.204367,"twenty":-14.908192,"median":-2.636466,"eighty":-1.688248,"marketCap":36657328},{"date":"2023-09-29","current":-1.152455,"twenty":-14.784291,"median":-2.613282,"eighty":-1.672875,"marketCap":35077270},{"date":"2023-10-06","current":-1.017587,"twenty":-14.720479,"median":-2.595591,"eighty":-1.660148,"marketCap":30972282},{"date":"2023-10-13","current":-0.986335,"twenty":-14.644703,"median":-2.581926,"eighty":-1.631815,"marketCap":30021087},{"date":"2023-10-20","current":-0.996718,"twenty":-14.592857,"median":-2.545008,"eighty":-1.604995,"marketCap":30337099},{"date":"2023-10-27","current":-1.038248,"twenty":-14.58488,"median":-2.535787,"eighty":-1.598161,"marketCap":31601145},{"date":"2023-11-03","current":-1.038248,"twenty":-14.487647,"median":-2.512992,"eighty":-1.579913,"marketCap":31601145},{"date":"2023-11-10","current":-1.04863,"twenty":-14.428142,"median":-2.508124,"eighty":-1.53388,"marketCap":31917156},{"date":"2023-11-17","current":-0.975284,"twenty":-14.427204,"median":-2.499738,"eighty":-1.499342,"marketCap":29460407},{"date":"2023-11-24","current":-0.773116,"twenty":-14.345588,"median":-2.483183,"eighty":-1.472685,"marketCap":23353524},{"date":"2023-12-01","current":-0.879023,"twenty":-14.181765,"median":-2.475843,"eighty":-1.42357,"marketCap":26552637},{"date":"2023-12-08","current":-1.045507,"twenty":-14.054449,"median":-2.460191,"eighty":-1.396066,"marketCap":31581643},{"date":"2023-12-15","current":-2.478208,"twenty":-13.958732,"median":-2.457636,"eighty":-1.392378,"marketCap":74859244},{"date":"2023-12-22","current":-1.846609,"twenty":-13.958732,"median":-2.452578,"eighty":-1.396066,"marketCap":55780526},{"date":"2023-12-29","current":-2.032702,"twenty":-13.958732,"median":-2.452527,"eighty":-1.401599,"marketCap":61401819},{"date":"2024-01-05","current":-1.989757,"twenty":-13.925599,"median":-2.452527,"eighty":-1.402377,"marketCap":60104598},{"date":"2024-01-12","current":-2.204479,"twenty":-13.852506,"median":-2.432089,"eighty":-1.40765,"marketCap":66590705},{"date":"2024-01-19","current":-2.063553,"twenty":-13.785989,"median":-2.419201,"eighty":-1.41082,"marketCap":62333748},{"date":"2024-01-26","current":-1.86293,"twenty":-13.736241,"median":-2.404062,"eighty":-1.42357,"marketCap":56273522},{"date":"2024-02-02","current":-1.719628,"twenty":-13.704713,"median":-2.380995,"eighty":-1.448386,"marketCap":51944790},{"date":"2024-02-09","current":-1.748288,"twenty":-13.628938,"median":-2.367158,"eighty":-1.456925,"marketCap":52810536},{"date":"2024-02-16","current":-1.576325,"twenty":-13.58292,"median":-2.350965,"eighty":-1.460613,"marketCap":47616057},{"date":"2024-02-23","current":-1.447353,"twenty":-13.558377,"median":-2.345229,"eighty":-1.458769,"marketCap":43720198},{"date":"2024-03-01","current":-1.590655,"twenty":-13.444252,"median":-2.3299,"eighty":-1.456925,"marketCap":48048930},{"date":"2024-03-08","current":-1.748288,"twenty":-13.380441,"median":-2.319682,"eighty":-1.458769,"marketCap":52810536},{"date":"2024-03-15","current":-1.662307,"twenty":-13.376453,"median":-2.304353,"eighty":-1.46812,"marketCap":50213297},{"date":"2024-03-22","current":-1.803218,"twenty":-13.344547,"median":-2.289025,"eighty":-1.47731,"marketCap":54109156},{"date":"2024-03-28","current":-1.745515,"twenty":-13.280736,"median":-2.278806,"eighty":-1.482493,"marketCap":52377663},{"date":"2024-04-05","current":-1.615683,"twenty":-13.260795,"median":-2.273092,"eighty":-1.493809,"marketCap":48481804},{"date":"2024-04-12","current":-1.65896,"twenty":-13.220913,"median":-2.258664,"eighty":-1.493809,"marketCap":49780423},{"date":"2024-04-19","current":-1.514703,"twenty":-12.881915,"median":-2.256631,"eighty":-1.482493,"marketCap":45451691},{"date":"2024-04-26","current":-1.500277,"twenty":-12.662564,"median":-2.248149,"eighty":-1.482493,"marketCap":45018818},{"date":"2024-05-03","current":-1.496325,"twenty":-12.582799,"median":-2.24304,"eighty":-1.482493,"marketCap":44900232},{"date":"2024-05-10","current":-1.432162,"twenty":-12.522976,"median":-2.231493,"eighty":-1.471426,"marketCap":44460034},{"date":"2024-05-17","current":-1.446342,"twenty":-12.363448,"median":-2.22179,"eighty":-1.466146,"marketCap":44900232},{"date":"2024-05-24","current":-1.47456,"twenty":-12.249186,"median":-2.21305,"eighty":-1.460522,"marketCap":45776227},{"date":"2024-05-31","current":-1.463976,"twenty":-12.22279,"median":-2.204479,"eighty":-1.456925,"marketCap":45447667},{"date":"2024-06-07","current":-1.606109,"twenty":-12.175695,"median":-2.195832,"eighty":-1.459803,"marketCap":49860062},{"date":"2024-06-14","current":-2.387844,"twenty":-12.164651,"median":-2.194059,"eighty":-1.462594,"marketCap":74128234},{"date":"2024-06-21","current":-1.307913,"twenty":-12.137654,"median":-2.185365,"eighty":-1.456925,"marketCap":40602857},{"date":"2024-06-28","current":-1.278207,"twenty":-12.111271,"median":-2.180423,"eighty":-1.456032,"marketCap":39680667},{"date":"2024-07-05","current":-1.134937,"twenty":-12.029972,"median":-2.177406,"eighty":-1.446342,"marketCap":35232973},{"date":"2024-07-12","current":-1.194064,"twenty":-11.984449,"median":-2.176166,"eighty":-1.442646,"marketCap":37068529},{"date":"2024-07-15","current":-1.247649,"twenty":-11.984409,"median":-2.173979,"eighty":-1.442545,"marketCap":38732002},{"date":"2024-08-02","current":-1.208135,"twenty":-11.984369,"median":-2.171792,"eighty":-1.44243,"marketCap":37505356},{"date":"2024-08-09","current":-0.972336,"twenty":-11.964627,"median":-2.163939,"eighty":-1.432162,"marketCap":30185193},{"date":"2024-08-16","current":-0.882654,"twenty":-11.805099,"median":-2.157724,"eighty":-1.410954,"marketCap":28207850},{"date":"2024-08-23","current":-0.761433,"twenty":-11.486042,"median":-2.153127,"eighty":-1.401599,"marketCap":24333891},{"date":"2024-08-30","current":-0.760116,"twenty":-11.473771,"median":-2.145961,"eighty":-1.383157,"marketCap":24291783},{"date":"2024-09-06","current":-0.49469,"twenty":-11.473771,"median":-2.139282,"eighty":-1.363657,"marketCap":15809309},{"date":"2024-09-13","current":-0.440961,"twenty":-11.406278,"median":-2.139215,"eighty":-1.340739,"marketCap":14092228},{"date":"2024-09-20","current":-0.470095,"twenty":-11.213923,"median":-2.135742,"eighty":-1.289457,"marketCap":15023289},{"date":"2024-09-27","current":-0.417244,"twenty":-11.170053,"median":-2.130061,"eighty":-1.276954,"marketCap":13334280},{"date":"2024-10-04","current":-0.3865,"twenty":-11.143056,"median":-2.126474,"eighty":-1.252451,"marketCap":12351754},{"date":"2024-10-11","current":-0.336577,"twenty":-11.055316,"median":-2.117497,"eighty":-1.235515,"marketCap":10756319},{"date":"2024-10-18","current":-0.33687,"twenty":-10.900082,"median":-2.109319,"eighty":-1.21758,"marketCap":10765676},{"date":"2024-10-25","current":-0.468631,"twenty":-10.812342,"median":-2.095323,"eighty":-1.203755,"marketCap":14976502},{"date":"2024-10-31","current":-0.39543,"twenty":-10.748223,"median":-2.092695,"eighty":-1.194032,"marketCap":12637154},{"date":"2024-11-08","current":-0.484003,"twenty":-10.522122,"median":-2.089364,"eighty":-1.182279,"marketCap":15467765},{"date":"2024-11-15","current":-0.493189,"twenty":-10.383762,"median":-2.069928,"eighty":-1.172361,"marketCap":15720414},{"date":"2024-11-22","current":-0.727675,"twenty":-10.366889,"median":-2.063526,"eighty":-1.163203,"marketCap":23194640},{"date":"2024-11-29","current":-0.692883,"twenty":-10.333143,"median":-2.052343,"eighty":-1.153748,"marketCap":22085647},{"date":"2024-12-06","current":-0.682195,"twenty":-10.285898,"median":-2.047072,"eighty":-1.146883,"marketCap":21744975},{"date":"2024-12-13","current":-0.66082,"twenty":-10.120541,"median":-2.043874,"eighty":-1.13907,"marketCap":21063633},{"date":"2024-12-20","current":-0.546666,"twenty":-9.880941,"median":-2.034998,"eighty":-1.134188,"marketCap":17424974},{"date":"2024-12-27","current":-0.578502,"twenty":-9.786451,"median":-2.03022,"eighty":-1.134038,"marketCap":18439739},{"date":"2025-01-03","current":-0.63717,"twenty":-9.448987,"median":-2.021551,"eighty":-1.122855,"marketCap":20309807},{"date":"2025-01-10","current":-0.710847,"twenty":-9.408492,"median":-2.010187,"eighty":-1.116819,"marketCap":22658264},{"date":"2025-01-17","current":-0.674464,"twenty":-9.371371,"median":-2.008908,"eighty":-1.107887,"marketCap":21498532},{"date":"2025-01-24","current":-0.652179,"twenty":-9.364622,"median":-2.004072,"eighty":-1.101073,"marketCap":20788196},{"date":"2025-01-31","current":-0.563721,"twenty":-9.324126,"median":-2.001642,"eighty":-1.097961,"marketCap":17968598},{"date":"2025-02-07","current":-0.629894,"twenty":-9.287005,"median":-1.998049,"eighty":-1.084711,"marketCap":20077861},{"date":"2025-02-14","current":-0.734724,"twenty":-8.480466,"median":-1.989757,"eighty":-1.079412,"marketCap":23419339},{"date":"2025-02-21","current":-0.65036,"twenty":-7.873031,"median":-1.984857,"eighty":-1.069395,"marketCap":20730210},{"date":"2025-02-28","current":-0.576228,"twenty":-7.761668,"median":-1.963783,"eighty":-1.052376,"marketCap":18367256},{"date":"2025-03-07","current":-0.58828,"twenty":-7.74142,"median":-1.954613,"eighty":-1.046541,"marketCap":18751417},{"date":"2025-03-14","current":-0.514603,"twenty":-7.684052,"median":-1.94723,"eighty":-1.038248,"marketCap":16402960},{"date":"2025-03-21","current":-0.621782,"twenty":-7.576063,"median":-1.937378,"eighty":-1.029162,"marketCap":18925165},{"date":"2025-03-28","current":-0.555572,"twenty":-7.474824,"median":-1.932498,"eighty":-1.018376,"marketCap":16909948},{"date":"2025-04-04","current":-0.430361,"twenty":-7.454576,"median":-1.923725,"eighty":-1.015188,"marketCap":13098912},{"date":"2025-04-11","current":-0.392718,"twenty":-7.417455,"median":-1.910326,"eighty":-1.00529,"marketCap":11953164},{"date":"2025-04-17","current":-0.42075,"twenty":-7.400582,"median":-1.906138,"eighty":-0.992946,"marketCap":12806381},{"date":"2025-04-25","current":-0.493901,"twenty":-7.363461,"median":-1.902764,"eighty":-0.983856,"marketCap":15032871},{"date":"2025-05-02","current":-0.453588,"twenty":-7.316216,"median":-1.899535,"eighty":-0.976534,"marketCap":13805863},{"date":"2025-05-09","current":-0.497478,"twenty":-7.277408,"median":-1.883407,"eighty":-0.972926,"marketCap":13643346},{"date":"2025-05-16","current":-0.438552,"twenty":-7.228476,"median":-1.871872,"eighty":-0.963991,"marketCap":12027282},{"date":"2025-05-23","current":-0.439545,"twenty":-7.221726,"median":-1.86293,"eighty":-0.937651,"marketCap":12054514},{"date":"2025-05-30","current":-0.507727,"twenty":-7.221726,"median":-1.86244,"eighty":-0.918094,"marketCap":13924416},{"date":"2025-06-06","current":-0.452491,"twenty":-7.13736,"median":-1.85343,"eighty":-0.881988,"marketCap":12409571},{"date":"2025-06-13","current":-0.298898,"twenty":-7.120487,"median":-1.846259,"eighty":-0.836826,"marketCap":8197267},{"date":"2025-06-20","current":-0.267501,"twenty":-7.09349,"median":-1.844209,"eighty":-0.789983,"marketCap":7336209},{"date":"2025-06-27","current":-0.271268,"twenty":-7.086741,"median":-1.819939,"eighty":-0.773116,"marketCap":7439536},{"date":"2025-07-03","current":-0.27378,"twenty":-7.076617,"median":-1.803218,"eighty":-0.769837,"marketCap":7508421},{"date":"2025-07-11","current":-0.287595,"twenty":-7.039496,"median":-1.795936,"eighty":-0.758828,"marketCap":7887286},{"date":"2025-07-18","current":-0.276292,"twenty":-6.978752,"median":-1.788792,"eighty":-0.734997,"marketCap":7577306},{"date":"2025-07-25","current":-0.302665,"twenty":-6.951755,"median":-1.776194,"eighty":-0.730523,"marketCap":8300594},{"date":"2025-08-01","current":-0.267501,"twenty":-6.941631,"median":-1.775035,"eighty":-0.721671,"marketCap":7336209},{"date":"2025-08-08","current":-0.270013,"twenty":-6.924758,"median":-1.766314,"eighty":-0.708482,"marketCap":7405094},{"date":"2025-08-15","current":-0.456062,"twenty":-6.912947,"median":-1.751998,"eighty":-0.69467,"marketCap":10895320},{"date":"2025-08-22","current":-0.425658,"twenty":-6.894386,"median":-1.74829,"eighty":-0.690108,"marketCap":10168966},{"date":"2025-08-25","current":-0.429458,"twenty":-6.889324,"median":-1.748288,"eighty":-0.688198,"marketCap":10259760}],"updateTime":1756282318510},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INAB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531578034","title":"IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531578034","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531578034?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"NEW YORK, April 29, 2025  -- IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences.“The breadth of data we’re presenting at upcoming medical conferences reflects the scientific rigor and clinical potential of IN8bio’s gamma-delta T cell platform,” said William Ho, CEO and co-founder, IN8bio. “From our INB-200/400 program in newly glioblastoma to our novel T cell engager technologies, we are expanding the therapeutic applications of this unique class of therapies. These presentations highlight IN8bio’s capabilities, know-how in manufacturing, and the clinical potential of our programs to help patients with significant unmet needs across oncology and immune-mediated diseases.”Poster Presentation Title: INB-600: A Novel T Cell Engager Pla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-present-clinical-preclinical-data-120000930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INAB","BK4139","BK4539"],"gpt_icon":0},{"id":"2530763409","title":"IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2530763409","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530763409?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome . INB-600 TCE platform significantly expands both Vδ1+ and Vδ2+ subsets to address the reduced cell counts that have limited earlier γδ TCE therapies in cancer patients. INB-619  and INB-633  consistently show potent and highly targeted anti-cancer activity with deep tumor cell depletion in preclinical studies without the increased secretion of dangerous cytokines such as IL-6. Targeted B cell elimination  highlights potential applications in B cell–driven autoimmune diseases as well as cancer. INB-619 and INB-633 both triggered strong and specific, linear dose-related killing of leukemia cells  at low picomolar concentrations.Both molecules activated and expanded two key γδ T cell subsets , which is critical since most","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-unveils-promising-data-next-120000932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4006","BK4539","INAB","IE00B19Z4B17.USD","IE0031619046.USD","IE00B66KJ199.SGD","LU2065731478.USD","IE00B7SZL793.SGD","CRS","BK4139"],"gpt_icon":0},{"id":"2523945691","title":"IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945691","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945691?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"NEW YORK, March  31, 2025  (GLOBE NEWSWIRE) -- IN8bio, Inc.(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune disea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052244/0/en/IN8bio-to-Present-New-Preclinical-Data-on-Novel-Gamma-Delta-%CE%B3%CE%B4-T-cell-Engager-Platform-for-Cancer-Immunotherapy-at-AACR-Annual-Meeting-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","INAB"],"gpt_icon":0},{"id":"2520113770","title":"Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520113770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520113770?lang=en_us&edition=fundamental","pubTime":"2025-03-20 06:55","pubTimestamp":1742424905,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $2.00. The company’s sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-in8bio-inab-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-sticks-to-their-buy-rating-for-in8bio-inab-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","INAB"],"gpt_icon":0},{"id":"2520678246","title":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678246","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678246?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:05","pubTimestamp":1742299500,"startTime":"0","endTime":"0","summary":"NEW YORK, March 18, 2025  -- IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360°  Conference 2025, held March 24-26, 2025, in Boston, MA.William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, “Tackling the Tough Questions in IO for Autoimmunity Disease.” After, he will Chair the session, “State of the IO Market, Investments and Deals Plenary.”During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of “Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager,” and provide a corporate overview of IN8bio’s recently announced INB-619, T cell engager program for oncology and autoimmune diseases.As co-chair and panel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-participate-11th-annual-immuno-120500823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","INAB"],"gpt_icon":0},{"id":"2520522383","title":"INAB: Introducing INB-600, A γδ T Cell Engager Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522383","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522383?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:31","pubTimestamp":1742203860,"startTime":"0","endTime":"0","summary":"Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc.  reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme  and acute myeloid leukemia  efforts and presentations at multiple investor and scientific conferences.The most important information shared related to the INB-100 patients. Trial data was updated by about four months from early August 2024 to January 17th, 2025 and were presented at the Transplantation & Cellular Therapy  Meetings in February. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of both progression free survival  and overall survival .General & administrative expenses were $12.6 million, falling 6.5% from $13.5 million. The decrease was pri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-introducing-inb-600-t-093100072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065731478.USD","BK4211","OS","BK4195","INAB","IE0031619046.USD","BK4139","IE00B19Z4B17.USD","CR","IE00B66KJ199.SGD","BK4161","INB","BK4539","IE00B7SZL793.SGD","PFS","CRS","BK4006","BK4097"],"gpt_icon":0},{"id":"2519180947","title":"HC Wainwright Adjusts IN8bio Price Target to $6 From $8, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2519180947","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519180947?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:54","pubTimestamp":1741956858,"startTime":"0","endTime":"0","summary":"IN8bio (INAB) has an average rating of Buy and mean price target of $3.62, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and res","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INAB"],"gpt_icon":0},{"id":"2519488809","title":"IN8bio Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2519488809","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519488809?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:48","pubTimestamp":1741956480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INAB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 08:48 ET (12:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INAB"],"gpt_icon":0},{"id":"2519817418","title":"IN8bio Reports Progress in Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2519817418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519817418?lang=en_us&edition=fundamental","pubTime":"2025-03-14 12:14","pubTimestamp":1741925653,"startTime":"0","endTime":"0","summary":"In8bio, Inc. ( ($INAB) ) has released its Q4 earnings. Here is a breakdown of the information In8bio, Inc. presented to its investors. IN8bio, Inc....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/in8bio-reports-progress-in-cancer-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/in8bio-reports-progress-in-cancer-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BK4539","BK4139","INAB","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2519860612","title":"IN8BIO Q4 Net Income USD -6.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2519860612","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519860612?lang=en_us&edition=fundamental","pubTime":"2025-03-14 05:52","pubTimestamp":1741902739,"startTime":"0","endTime":"0","summary":"March 13 (Reuters) - IN8BIO, Inc. ::*IN8BIO Q4 NET INCOME USD -6.4 MILLION*IN8BIO: MAINTAINING CASH POSITION TO SUPPORT OPERATIONS & ACHIEVEMENT OF ANTICIPATED DEVELOPMENT MILESTONES THROUGHOUT 2025 &","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nRSD6s4dJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","INAB"],"gpt_icon":0},{"id":"2519691818","title":"IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2519691818","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519691818?lang=en_us&edition=fundamental","pubTime":"2025-03-14 04:05","pubTimestamp":1741896300,"startTime":"0","endTime":"0","summary":"Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, includingglioblastoma (GBM) and  100% of treated Acute Myeloid Leukemia (AML) p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042590/0/en/IN8bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","CRS","BK4006","BK4139","IE00B7SZL793.SGD","INAB","IE00B19Z4B17.USD","BK4539","IE00B66KJ199.SGD","IE0031619046.USD"],"gpt_icon":0},{"id":"2516632610","title":"IN8bio announces gamma-delta T cell enager platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516632610?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:36","pubTimestamp":1741012614,"startTime":"0","endTime":"0","summary":"IN8bio (INAB) unveiled INB-600, its next generation gammadelta T cell-based TCE platform. It is designed to address one of the biggest shortcomings...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/in8bio-announces-gamma-delta-t-cell-enager-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/in8bio-announces-gamma-delta-t-cell-enager-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","INAB"],"gpt_icon":0},{"id":"2516631265","title":"IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631265","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631265?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:28","pubTimestamp":1741012080,"startTime":"0","endTime":"0","summary":"Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19, eradica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/03/3035747/0/en/IN8bio-Announces-Advanced-Gamma-Delta-%CE%B3%CE%B4-T-cell-Engager-TCE-Platform-for-Oncology-and-Autoimmune-Diseases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRS","AEIS","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4539","LU2065731478.USD","BK4157","BK4006","IE00B19Z4B17.USD","IE0031619046.USD","INAB","BK4139"],"gpt_icon":0},{"id":"2513272638","title":"IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2513272638","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513272638?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 24, 2025  -- IN8bio, Inc. , a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the:. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-present-h-c-wainwright-130000951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","INAB"],"gpt_icon":0},{"id":"2512484426","title":"INAB: Continued Survival in INB-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2512484426","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512484426?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:11","pubTimestamp":1739963460,"startTime":"0","endTime":"0","summary":"IN8bio, Inc  updates survival data for its INB-100 trial in a February 11thpress release in preparation for presentation of data at the Transplantation & Cellular Therapy  Meetings in Hawaii last week. Data for patients enrolled in the trial were updated from early August 2024 to January 17th, 2025. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of progression free survival  and overall survival . Since our last update, IN8bio has participated in multiple investor and scientific conferences, including Biotech Showcase, Noble’s Emerging Growth Conference, the American Society of Hematology Annual Meeting and the TCT meetings.The results are remarkable as real-world survival rates for AML patients following hematopoietic stem cell transplantation  are lower. For example, the Center for International Blood and Marrow Transplant Research  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-continued-survival-inb-100-111100490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INB","IE0031619046.USD","CR","BK4539","BK4097","IE00B7SZL793.SGD","INAB","BK4195","BK4006","IE00B66KJ199.SGD","BK4161","BK4139","HSCT","OS","CRS","BK4211","PFS","LU2065731478.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2511937176","title":"IN8bio presented Phase 1 data on INB-100 at 2025 TCT","url":"https://stock-news.laohu8.com/highlight/detail?id=2511937176","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511937176?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:05","pubTimestamp":1739541953,"startTime":"0","endTime":"0","summary":"IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, TCT, Me...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/in8bio-presented-phase-1-data-on-inb-100-at-2025-tct?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/in8bio-presented-phase-1-data-on-inb-100-at-2025-tct?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","INB","INAB"],"gpt_icon":0},{"id":"2511569349","title":"IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2511569349","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511569349?lang=en_us&edition=fundamental","pubTime":"2025-02-14 22:00","pubTimestamp":1739541600,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 14, 2025  -- February 14, 2025– IN8bio, Inc. , a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy  Meetings in Hawaii. The data, previously announced, reinforce INB-100’s potential to significantly reduce post-transplant relapse in high-risk acute myeloid leukemia  patients, positioning this gamma-delta T cell therapy as a promising approach in hematologic oncology.The latest findings demonstrate that INB-100 continues to deliver long-term remissions, with no AML patient relapses observed to date with a median follow-up of 20.1 months. The 1-year progression-free survival  rate across all leukemia patients stands at 90.9%, and 1-year overall survival  is 100%, outperforming real-world historical controls. These data demonstrate that results for INB-100 do not appear to be due to imbalances in pa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/in8bio-presents-positive-phase-1-140000114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","PFS","INAB","BK4139","OS","IE00B19Z4B17.USD","BK4211","IE0031619046.USD","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4006","CRS","BK4097","LU2065731478.USD","BK4539"],"gpt_icon":0},{"id":"2510535261","title":"Mizuho Securities Keeps Their Buy Rating on IN8bio (INAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510535261","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510535261?lang=en_us&edition=fundamental","pubTime":"2025-02-12 04:55","pubTimestamp":1739307313,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio (INAB – Research Report) today and set a price target of $2.00. The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-in8bio-inab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-in8bio-inab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INAB","MFG"],"gpt_icon":0},{"id":"2510334588","title":"BUZZ-IN8bio rises on early-stage data from cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2510334588","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510334588?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:44","pubTimestamp":1739292247,"startTime":"0","endTime":"0","summary":"BUZZ-IN8bio rises on early-stage data from cancer therapy ** Shares of the New York-based drug developer IN8bio INAB.O rises 17.5% to 31 cents ** Co says early-stage trial showed its experimental canc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nL4N3P2198:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","INAB"],"gpt_icon":0},{"id":"2510937339","title":"Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), IN8bio (INAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510937339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510937339?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:10","pubTimestamp":1739290206,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beyond Air (XAIR – Research Report) and IN8bio (INAB...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beyond-air-xair-in8bio-inab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beyond-air-xair-in8bio-inab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","XAIR","BK4139","HCSG","BK4137","INAB","BK4539"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":46,"code":"91000000","status":"200"}]}}